Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic castration-resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine tetramethylene phosphonate (Sm-153-EDTMP; Quadramet(®)), a radiopharmaceutical, binds osteoblastic bone lesions and emits beta particles causin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Heery, Christopher R., Madan, Ravi A., Stein, Mark N., Stadler, Walter M., Di Paola, Robert S., Rauckhorst, Myrna, Steinberg, Seth M., Marté, Jennifer L., Chen, Clara C., Grenga, Italia, Donahue, Renee N., Jochems, Caroline, Dahut, William L., Schlom, Jeffrey, Gulley, James L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340090/
https://ncbi.nlm.nih.gov/pubmed/27486817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10883
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky